Oncological diseases are continuing to pose an ever-greater threat. According to forecasts, the global morbidity rate will virtually double by 2030. In the meantime, the COVID-19 pandemic has led to medical centres having to temporarily shift their focus. Nevertheless, amid the intense pressure that the healthcare system has come under, one fact remains indisputable – no crisis should affect the treatment of patients with oncological diseases. These are people for whom having timely access to diagnosis and treatment can be the difference between life and death. A federal project to combat oncological diseases is currently being implemented in Russia. A number of steps now need to be taken to increase its impact. The experience of providing medical care to oncological patients during the pandemic needs to be examined in its entirety, with amendments made accordingly. At the same time, there needs to be a particular focus on the quality of care for key afflictions. Almost 50% of all paediatric oncological patients suffer from oncohaematological diseases. When diagnosis and treatment is provided early, and to a high standard, more than 80% of children suffering from malignant blood diseases are able to recover and achieve steady, prolonged remission.
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Managing Director Russia & CIS, Janssen, pharmaceutical division of Johnson & Johnson, Director General Johnson & Johnson LLC
Katerina started her career with Johnson & Johnson back in 2001. With the background of the criminal lawyer (degree with honors, the International University in Moscow), she joined Janssen, pharmaceutical division of Johnson & Johnson as an assistant to a marketing team, and in 9 months was promoted to the marketeer position. Throughout her 18-year career with Janssen, Katerina has consistently demonstrated integrity and strong results. She launched a whole range of new products and worked across a number of therapeutic areas, holding various positions of increasing level of responsibility in sales, marketing, quality and market access departments.
Katerina has been a member of Janssen Russia board of directors since 2010 and was appointed Country Manager Russia in 2015; she was promoted to the position of Managing Director Janssen Russia & CIS in 2017. In April 2019 she was appointed Director General Johnson & Johnson LLC.
Katerina was one of the firsts leaders to implement and operate in a matrix team structure, she successfully led the business through a turnover and launched start-up business units within the company; under her leadership Janssen became a compliance benchmark for the Russian pharmaceutical industry.
Since 2015, Katerina has been a member of the board of directors of the Association of International Pharmaceutical Manufacturers (AIPM) and the Innovative Pharma, Association of the pharmaceutical companies “Pharmaceutical Innovations”. In 2019 Katerina was elected to the board of directors of AmCham. Since November, 2019 Katerina is a member of the “regulatory guillotine” governmental working group, for healthcare sector.
Katerina is a regular Forbes magazine contributor, speaker of the prominent events (Second Eurasian Women’s Forum, Gaydar Economic Forum, SPIEF, etc.) In 2019, was recognized as the Business Woman of the year in the “Pharma” nomination by Ernst & Young.